Amna Anwar

Abstract Accurate prediction of diseases from multiple co-occurring symptoms remains an important challenge in intelligent healthcare systems. Machine-learning models can support early symptom-based risk screening; however, their clinical use is limited by dataset quality, lack of external validation, interpretability concerns, and the risk of overstated diagnostic claims.

Choosing an AI code review agent is no longer about novelty; it's about review quality, team adoption, integration friction, and even your engineering culture. Your team is drowning in pull requests. Should you pick CodeRabbit for deep contextual reviews? Copilot for seamless GitHub integration? Or Gemini for Google's emerging AI? Usage data tells part of the story, but real-world trade-offs go deeper.

I analyzed 40.3 million public pull requests from 2022-2025. The data is brutal: GitHub Copilot now dominates organizational adoption despite CodeRabbit processing more total PRs. This isn't a hot take. It's what 40M PRs told us. The Uncomfortable Truth CodeRabbit was built from the ground up for AI code review. It's genuinely good at what it does. 👑 CodeRabbit: #1 in PR volume for 2025. But that crown is slipping. Copilot overtook them in monthly PRs in November, and already leads in org adoption.